Der Report
Verifizierte Nachrichten zu Finanzierung, Hauptsitzen und Führungskräften der innovativsten Unternehmen der Welt
133 Berichte und es werden mehr
Craif Closes Approximately $33M Series D for Urine-Based Cancer Test
Craif closed an approximately $33 million Series D, made up of about $30.7 million in equity and about $3.3 million in debt and co-led by Granite-Integral and Tauns Co., Ltd., bringing total capital raised to roughly $88 million.
Rakuten Medical Raises $100M Series F | Photoimmunotherapy Cancer Treatment
Cancer treatment company Rakuten Medical secures $100 million Series F led by TaiAx for Phase 3 trials.
Vibrant Therapeutics Raises $61M Series B | Logic-Gated Cancer Immunotherapy
Clinical-stage biotech Vibrant Therapeutics secures $61 million Series B for tumor microenvironment-activated immunotherapies.
Guardant Health raises $360M Series F at $12B valuation
Guardant Health raises $360M in Series F at $12B valuation. Liquid biopsy cancer detection...
Freenome raises $270M Series C at $1.1B valuation
Freenome raises $270M in Series C at $1.1B valuation. Early cancer detection using AI...
Freenome raises $290M Series D at $1.1B valuation
Freenome raises $290M in Series D at $1.1B valuation. AI-driven early cancer detection...
Guardant Health raises $360M Series E at $2.15B valuation
Guardant Health raises $360M in Series E at $2.15B valuation. Blood-based cancer detection and monitoring...
Grail raises $390M Series D at $6.3B valuation
Grail raises $390M in Series D at $6.3B valuation. Multi-cancer early detection blood test...
DermaSensor raises $16M Series B at $85M valuation
DermaSensor raises $16M in Series B at $85M valuation. AI-powered skin cancer screening device for early detection...
9 Berichte angezeigt • Seite 1 • Kategorie: all
Bleiben Sie dem Markt voraus
Erhalten Sie wöchentliche Insights direkt in Ihren Posteingang. Kein Spam, nur Intelligence.